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Major depressive disorderPrescribing safe and effective medications is a challenge in psychiatry. While clinical use of pharmacogenomic
testing for individual genes has provided some clinical beneﬁt, it has largely failed to show clinical utility. How-
ever, pharmacogenomic testing that integrates relevant genetic variation frommultiple loci for each medication
has shown clinical validity, utility and cost savings in multiple clinical trials. While some challenges remain, the
evidence for the clinical utility of “combinatorial pharmacogenomics” is mounting. Expanding education of
pharmacogenomic testing is vital to implementation efforts in psychiatric treatment settings with the overall
goal of improving medication selection decisions.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Pharmacogenomics in psychiatry
Prescribing safe and effectivemedications is one of the greatest chal-
lenges in psychiatry. Large prospective clinical trials provide evidence
for these challengeswith increasingpoor response rates and intolerance
of treatment after a patient fails onemedication, which are exacerbated
with each subsequent medication failure (Warden et al., 2007).
Pharmacogenomics (PGx) utilizes genetic information to predict re-
sponses to medications on a personalized level based on known gene–
drug interactions for both pharmacokinetic (PK) and pharmacodynamic
(PD) genes. Pharmacokinetic response to neuropsychiatric medications
is largely driven by the cytochrome P450 system of enzymes expressed
in the liver. Metabolism of medications by these enzymes affects the
drug levels in the blood which will ultimately result in potential for ef-
ﬁcacy and/or side effects. For example, an individual can be a poor
metabolizer for a drugwhichwill result in high drug blood levels and in-
crease the potential for side effects. Pharmacodynamic genes predict re-
sponse to amedication at the site of action. As an example, the serotonin
transporter is encoded by SLC6A4 and has two main allelic variations, S
and L. Patients with the S/S genotype have reduced rates of remission
and response with selective serotonin reuptake inhibitor (SSRI) treat-
ment (Porcelli et al., 2012).
Both pharmacokinetic and pharmacodynamic genetic differences
contribute to the variability of response and potential for side effects
for a patient. Select medications are exclusively metabolized by a singleth Mason-Montgomery Road,
ner).
. This is an open access article undergene and will likely only be pharmacokinetically impacted by genetic
variation at that single locus. For example, CYP2D6 copy number varia-
tion has been demonstrated to have a signiﬁcant impact on plasma
levels of nortriptyline, which is exclusively metabolized by CYP2D6
(Dalén et al., 1998). However, the majority of medications are metabo-
lized by multiple enzymes, and can have considerable variability in re-
ceptor and transporter binding proﬁles. Given this complexity, it is
unsurprising that single gene testing has shown limited clinical beneﬁt
for patients in ‘real world’ settings (Evaluation of Genomic Applications
in Practice and Prevention (EGAPP) Working Group, 2007). However,
synchronously evaluating the combination of PK–PK, PK–PD, and PD–
PD gene interactions for a given individual has improved the clinical ef-
fectiveness of pharmacogenomic testing (Altar et al., 2015; Hall-Flavin
et al., 2012, 2013; J. G. Winner et al., 2013). For example, the SSRI
citalopram is metabolized by 3 different enzymes (CYP2C19, CYP2D6,
and CYP3A4) (Olesen and Linnet, 1999). Additionally, the serotonin
transporter (SLC6A4) is the pharmacodynamic site of action for
citalopram (Mrazek et al., 2009). Identifying the genotypic differences
concomitantly for these four genes will lead to a combinatorial compos-
ite phenotype for citalopram and yield the most accurate clinically ‘ac-
tionable’ information. This combinatorial process allows the
healthcare provider to assimilate complex layers of genetic information
into information that supports medication decisions.2. Clinical validity
Criteria for implementation of PGx information have been proposed
(Hall-Flavin et al., 2013; Rundell et al., 2011), including ability to predictthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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gration into clinical practice (ease of use), and effective predictions to
improve clinical outcome (clinical utility).
Clinical validity is the accuracy of a genetic test to predict a stated
clinical outcome such as the likelihood of response to treatment. Three
prospective clinical trials (two open-label trials and one placebo-
controlled double-blind trial) have demonstrated the clinical validity
of treatment guided by combinatorial pharmacogenomics in Major De-
pressive Disorder (Hall-Flavin et al., 2012, 2013; J. G. Winner et al.,
2013). Each of the three studies utilized GeneSight Psychotropic as the
combinatorial PGx tool for physicians to help guide medication selec-
tion decisions. Based on an algorithm, the GeneSight report categorizes
medications into three possible advisory categories: Use as Directed;
Use with Caution; or Use with Increased Caution and with more Fre-
quent Monitoring, which are color coded green, yellow, and red,
respectively.
The outcomes of the standard of care groupswere analyzed to assess
the clinical validity and predictive capability of the pharmacogenomic
report. In the standard of care groups, the patients were blinded to
their genetic information. However, after completion of the study, the
PGx information was used to determine the clinical validity (predictive
ability of response and intolerable treatment). In all three prospective
clinical trials patients on red categorymedications, indicating a negative
gene–drug interaction, experienced the worst outcomes based on the
17-itemHamilton Rating Scale for Depression (HAM-D17; Fig. 1).More-
over, in a pooled analysis of the three studies, combinatorial
pharmacogenomics showed this ability to predict poor outcomes,
whereas single geneswere not predictive (Altar et al., 2015). The clinical
validity of the GeneSight combinatorial PGx information is shown by its
predictive capability to determine that patients who are placed on red
category medications have increased likelihood of poorer outcomes.3. Clinical utility
Clinical utility represents the improvement in outcomes in PGx test-
ed individuals compared to standard of care. Aswith the clinical validity
of PGx testing, three clinical trials have studied the clinical utility of
combinatorial PGx information compared to standard of care. The ﬁrst
prospective, open-label trial identiﬁed a signiﬁcant reduction in the
GeneSight guided group compared to the standard of care group
based on the HAM-D17 as well as the 16 item Clinician Rated Quick In-
ventory of Depressive Symptomatology (QIDS-C16). Thiswas replicated
by a much larger study, which resulted in a signiﬁcantly improved re-
sponse on the QIDS-C16 and HAM-D17, as well as the patient reportedFig. 1. Clinical outcomes of blinded subjects treated without pharmacogenom9 item Patient Health Questionnaire (PHQ-9), in the GeneSight guided
group compared to standard of care (Hall-Flavin et al., 2013). Finally,
the smaller placebo-controlled, double-blind study trended towards
similar clinical signiﬁcance showing improvement in the GeneSight
group compared to standard of care with double the likelihood of re-
sponse (J. G. Winner et al., 2013).4. Health economic outcomes
A number of trials have assessed the health resource utilization and
potential cost savings for patients with the use of genetic reports. In a
retrospective review, Chou et al. (2000) found that, among patients on
CYP2D6-dependent medications, those with poor or ultrarapid
CYP2D6 metabolism spent between $4000 and $6000 more in a one
year period. Ruaño et al. (2013) retrospectively found that individuals
with reduced CYP2D6 function averaged hospitalization length of stay
that was two days longer than those with normal or increased
CYP2D6 function. In a retrospective chart review using the GeneSight
Psychotropic report, patients that were on medications predicted to
yield the greatest gene–drug complications (i.e. “red category”medica-
tions) presented with signiﬁcantly increased total health care visits,
medical absence days, and disability claims compared to patients taking
green or yellow category medications, resulting in nearly $5200 greater
healthcare expenditures than those on genetically appropriate medica-
tions (J. Winner et al., 2013).
Most recently, larger scale analyses of health claims data have also
beenperformed. One retrospective analysis of health claimsdata analyzed
adherence rates and medication costs using a multi-genic (though not
combinatorial) report (Fagerness et al., 2014). Patients provided with ge-
netic testing (n=227)were signiﬁcantlymore adherent to theirmedica-
tions compared to standard of care (n = 454); however, pharmacy costs
increased in both the control and the genetically guided groups.
The largest economic study to date on combinatorial PGx testing
(n = 2166 patients with genetic testing and n = 10,880 standard of
care controls) analyzed total medication expenditures with the
GeneSight test compared to standard of care in a prospective design
(Allen et al., 2014a). Similar to the aforementioned retrospective study
(Fagerness et al., 2014), adherence rates improved in the tested group.
However, in this study using combinatorial PGx information, change
in pharmacy costs in the GeneSight group were $1035.60 lower per pa-
tient per year compared to the propensity matched standard of care
group. These costs improved even more for non-psychiatrists, patients
whose physicians followed the genetic report, and patientswith anxiety
disorders (Allen et al., 2014b).ic testing by GeneSight advisory category (pooled data from three trials).
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Pharmacogenomics is a quantitative tool to address the challenge of
selecting appropriate psychiatric medications. However, gene-by-gene
testing has shown limited clinical utility (Evaluation of Genomic
Applications in Practice and Prevention (EGAPP) Working Group, 2007;
Altar et al., 2015) in psychiatry. Combinatorial pharmacogenomics is
able to identify individuals who are on medication regimens that have
signiﬁcant gene–drug interactions based on information which simulta-
neously integrates multiple genetic factors. The combinatorial approach
combined with a streamlined platform to present this information has
demonstrated clinical validity and utility (Hall-Flavin et al., 2012, 2013;
J. G. Winner et al., 2013), as well as cost-effectiveness (Allen et al.,
2014a, 2014b; J. Winner et al., 2013). While some challenges still remain
(Hamilton, 2015; Howland, 2014), the clinical trial data highlighted here
provide evidence for the potential widespread beneﬁt of
pharmacogenomics in the psychiatric patient population.
As a value proposition, an interventionwhich offers the potential for
improved outcomes combinedwith ‘realworld’ cost savings is notewor-
thy. Recognizing the ongoing accumulation of clinical data in thepsychi-
atric pharmacogenomic ﬁeld and the enticing potential of a win–win
scenario (lower costs, better outcomes) for its patient population, the
Center for Medicare Services extensively evaluated the clinical validity,
clinical utility, and economic data presented here. After this compre-
hensive process, the Center for Medicare Services released a speciﬁc
coverage decision for the combinatorial GeneSight Psychotropic test
(Center for Medicare and Medicaid Services, 2014), thus increasing
the affordability and access to combinatorial testing for patients. Addi-
tionally, multiple private insurance companies and the U.S. Department
of Veterans Affairs have made decisions to cover the GeneSight combi-
natorial test. Expanding education of pharmacogenomic testing is vital
to implementation of these strategies in psychiatric treatment settings
with the overall goal of improving medication selection decisions.
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